 |
CHENGDU, China, July 27, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Firm”, 6990.HK) immediately introduced that it has obtained a scientific trial discover from the Middle for Drug Analysis (CDE) of the Nationwide Medical Merchandise Administration (NMPA) approving the Investigational New Drug (IND) software for its novel dual-payload ADC drug, SKB565, for the remedy of superior stable tumors. This marks the Firm’s first dual-payload ADC to enter the scientific stage.
SKB565 is developed utilizing the Firm’s proprietary OptiDC™ platform. That includes an progressive dual-payload design, SKB565 allows the direct supply of poisons and immunomodulators, two sorts of payload with complementary mechanisms of motion, to tumor tissue. In contrast with standard ADCs carrying solely toxins, SKB565 has a twin antitumor mechanism: it exactly targets and kills tumors whereas activating the immune system inside the tumor microenvironment to elicit an antitumor immune response, bringing enhanced and extra sturdy antitumor efficacy. In preclinical research, SKB565 demonstrated glorious antitumor exercise and security, with its excellent therapeutic potential to assist additional scientific growth.
Leveraging technological experience and platform benefits within the ADC subject, Kelun-Biotech has established a diversified pipeline of progressive molecules that includes high-value targets, differentiated designs, and international potential. Constructing on this basis, the Firm continues to advance its “ADC + IO” technique—on one hand by actively exploring high-quality mixture regimens, together with a number of ongoing scientific research evaluating ADCs together with PD-(L)1 monoclonal antibodies, in addition to the PD-1/VEGF bispecific antibody SKB118 together with its proprietary ADC portfolio; then again, the Firm is advancing built-in drug design methods by incorporating synergistic practical elements right into a single ADC molecule.
Dr. Michael Ge, CEO of Kelun-Biotech, mentioned, ” SKB565 is among the core consultant medication of our built-in ‘ADC + IO’ technique, leveraging the synergistic mechanism of its twin payloads to boost efficacy and overcome drug resistance. Twin-payload ADCs are rising as one of many key next-generation improvements within the ADC subject. The development of SKB565 into scientific stage not solely marks an necessary milestone within the achievements transformation of our know-how platform, but additionally substantiates the continued deepening of our innovation capabilities in ADCs. We are going to actively advance the scientific growth of novel drug conjugates reminiscent of SKB565, striving to ship better advantages to sufferers with most cancers as quickly as doable.”
About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and international collaboration of progressive organic medication and small molecule medication. Kelun-Biotech focuses on main illness areas reminiscent of stable tumors, autoimmune, and metabolic ailments, and in establishing a globalized drug growth and industrialization platform to handle the unmet medical wants in China and the remainder of world. Kelun-Biotech is dedicated to turning into a number one international enterprise within the subject of progressive medication. At current, Kelun-Biotech has greater than 30 ongoing key progressive drug tasks, of which 4 tasks with 8 indications have been authorised for advertising, 1 undertaking is within the NDA stage and greater than 10 tasks are within the scientific stage. Kelun-Biotech has established one of many world’s main proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC tasks with 5 indications authorised for advertising, and a number of ADC and novel DC belongings in scientific or preclinical analysis stage. For extra data, please go to https://en.kelun-biotech.com/.
